Unmasking IgAN: Achieving Earlier Diagnosis
Jonathan Barratt, MD, PhD
An De Vriese, MD, PhD
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Jörg Latus, MD
Translating Evidence into IgAN Care
The Evolving Role of Biomarkers in IgAN
Spotlight on Assessment: Tools That Capture CKD-aP
Federico Alberici, MD, PhD
Anastasia Liossatou, PhD, RN
Reading Between the Lines: What PROMs Reveal About Itch
What You Don’t See: A Patient’s View of Living with CKD-aP
Steven Fishbane, MD
Nancy Helou, PhD
Winning the CKD-aP Battle: A United Physician-Nurse Front
PSVT Without the Panic: Structured Care That Works
September 16, 2026
Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Sayna Norouzi, MD
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Crossing Home Plate – Building a Winning Team Culture
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
ASCVD Playbook | Closing the Gaps, One Inning at a Time
Leadoff Hitter – Spotting High-Risk Players
Small Ball Wins Games – Combination Therapy for Goal Attainment
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD